Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1β-induced interleukin 6 production and the myeloma proliferative component

Mayo Clinic Proceedings

Volumn 84, Issue 2, 2009, Pages 114-122

  Lust, John A ^a   Lacy, Martha Q ^a   Zeldenrust, Steven R ^a   Dispenzieri, Angela ^a   Gertz, Morie A ^a   Witzig, Thomas E ^a   Kumar, Shaji ^a   Hayman, Suzanne R ^a   Russell, Stephen J ^a   Buadi, Francis K ^a   Geyer, Susan M ^a   Campbell, Megan E ^a   Kyle, Robert A ^a   Rajkumar, S Vincent ^a   Greipp, Philip R ^a   Kline, Michael P ^a   Xiong, Yuning ^a   Moon Tasson, Laurie L ^a   Donovan, Kathleen A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; DEXAMETHASONE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; STROMAL CELL DERIVED FACTOR 1; ANTINEOPLASTIC AGENT; GLUCOCORTICOID; INTERLEUKIN 1;

ADULT; AGED; APOPTOSIS; ARTICLE; BLOOD LEVEL; CATARACT; CELL LABELING; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; COCULTURE; COLON PERFORATION; CREATININE BLOOD LEVEL; CYTOKINE PRODUCTION; FEMALE; HEART INFARCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; INFECTION; INJECTION SITE REACTION; LOW DRUG DOSE; MALE; MULTIPLE MYELOMA; MYELOMA CELL; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PLASMA CELL; PNEUMONIA; PROGRESSION FREE SURVIVAL; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SIDE EFFECT; THROMBOSIS; TREATMENT RESPONSE; BIOSYNTHESIS; BLOOD; BONE MARROW CELL; DRUG COMBINATION; DRUG EFFECT; MIDDLE AGED; MORTALITY; PATHOLOGY; TUMOR CELL LINE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE MARROW CELLS; C-REACTIVE PROTEIN; CELL LINE, TUMOR; DEXAMETHASONE; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; INTERLEUKIN-6; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PLASMA CELLS;

EID: 61449122079     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/84.2.114     Document Type: Article

References (34)

1. Kyle RA, Rajkumar SV. Treatment of multiple myeloma: an emphasis on new developments. Ann Med. 2006;38(2):111-115.
2. Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Hematol Oncol Clin North Am. 2007;21(6):1093-1113.
3. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121(5):749-757.
4. Kyle RA, Remstein ED, Therneau TM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007;356(25):2582-2590.
5. Weber DM, Dimopoulos MA, Moulopoulos LA, Delasalle KB, Smith T, Alexanian R. Prognostic features of asymptomatic multiple myeloma. Br J Haematol. 1997;97(4):810-814.
6. Dimopoulos MA, Moulopoulos A, Smith T, Delasalle KB, Alexanian R. Risk of disease progression in asymptomatic multiple myeloma. Am J Med. 1993;94(1):57-61.
7. Facon T, Menard JF, Michaux JL, et al; Groupe d'Etudes et de Recherche sur le Myelome (GERM). Prognostic factors in low tumour mass asymptomatic multiple myeloma: a report on 91 patients. Am J Hematol. 1995;48(2):71-75.
8. Wisloff F, Andersen P, Andersson TR, et al. Incidence and follow-up of asymptomatic multiple myeloma: the myeloma project of health region I in Norway. II. Eur J Haematol. 1991;47(5):338-341.
9. Kawano M, Hirano T, Matsuda T, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature. 1988;332(6159):83-85.
10. Schwab G, Siegall CB, Aarden LA, Neckers LM, Nordan RP. Characterization of an interleukin-6-mediated autocrine growth loop in the human multiple myeloma cell line, U266. Blood. 1991;77(3):587-593.
11. Klein B, Zhang XG, Jourdan M, et al. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood. 1989;73(2):517-526.
12. Portier M, Rajzbaum G, Zhang XG, et al. In vivo interleukin 6 gene expression in the tumoral environment in multiple myeloma. Eur J Immunol. 1991;21(7):1759-1762.
13. Hilbert DM, Kopf M, Mock BA, Köhler G, Rudikoff S. Interleukin 6 is essential for in vivo development of B lineage neoplasms. J Exp Med. 1995;182(1):243-248.
14. Xiong Y, Donovan KA, Kline MP, et al. Identification of two groups of smoldering multiple myeloma patients who are either high or low producers of interleukin-1. J Interferon Cytokine Res. 2006;26(2):83-95.
15. Donovan KA, Lacy MQ, Kline MP, et al. Contrast in cytokine expression between patients with monoclonal gammopathy of undetermined significance or multiple myeloma. Leukemia. 1998;12(4):593-600.
16. Lust JA, Donovan KA. The role of interleukin-1 beta in the pathogenesis of multiple myeloma. Hematol Oncol Clin North Am. 1999;13(6):1117-1125.
17. Lacy MQ, Donovan KA, Heimbach JK, Ahmann GJ, Lust JA. Comparison of interleukin-β1 expression by in situ hybridization in monoclonal gammopathy of undetermined significance and multiple myeloma. Blood. 1999;93(1):300-305.
18. Horton RM, Hunt HD, Ho SN, Pullen JK, Pease LR. Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. Gene. 1989;77(1):61-68.
19. Westendorf JJ, Ahmann GJ, Greipp PR, Witzig TE, Lust JA, Jelinek DF. Establishment and characterization of three myeloma cell lines that demonstrate variable cytokine responses and abilities to produce autocrine interleukin-6. Leukemia. 1996;10(5):866-876.
20. Feinman R, Koury J, Thames M, Barlogie B, Epstein J, Siegel DS. Role of NF-κB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2. Blood. 1999;93(9):3044-3052.
21. Witzig TE, Timm M, Larson D, Therneau T, Greipp PR. Measurement of apoptosis and proliferation of bone marrow plasma cells in patients with plasma cell proliferative disorders. Br J Haematol. 1999;104(1):131-137.
22. Greipp PR, Witzig TE, Gonchoroff NJ, et al. Immunofluorescence labeling indices in myeloma and related monoclonal gammopathies. Mayo Clin Proc. 1987;62(11):969-977.
23. Bataille R, Boccadoro M, Klein B, Durie B, Pileri A. C-reactive protein and β-2 microglobulin produce a simple and powerful myeloma staging system. Blood. 1992;80(3):733-737.
24. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood. 1996;87(6):2095-2147.
25. Hjorth M, Hellquist L, Holmberg E, Magnusson B, Rödjer S, Westin J; Myeloma Group of Western Sweden. Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I - a randomized study. Eur J Haematol. 1993;50(2):95-102.
26. Rajkumar SV, Gertz MA, Lacy MQ, et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia. 2003;17(4):775-779.
27. Musto P, Petrucci MT, Bringhen S, et al. Final analysis of a multicenter, randomised study comparing zoledronate vs observation in patients with asymptomatic myeloma [abstract 534]. Blood. 2007;110(11, pt 1):164a.
28. Greipp PR, Kyle RA. Clinical, morphological, and cell kinetic differences among multiple myeloma, monoclonal gammopathy of undetermined significance, and smoldering multiple myeloma. Blood. 1983;62(1):166-171.
29. Witzig TE, Kyle RA, O'Fallon WM, Greipp PR. Detection of peripheral blood plasma cells as a predictor of disease course in patients with smouldering multiple myeloma. Br J Haematol. 1994;87(2):266-272.
30. Dispenzieri A, Kyle RA, Katzmann JA, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering multiple myeloma [abstract 1487]. Blood. 2007;110(11, pt 1):445a.
31. 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma. Blood. 1988;72(1):219-223.
32. 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood. 1993;81(12):3382-3387.
33. Greipp PR, Lust JA. Pathogenetic relation between monoclonal gammopathies of undetermined significance and multiple myeloma. Stem Cells. 1995;13(suppl 2):10-21.
34. Huff CA, Matsui W, Smith BD, Jones RJ. The paradox of response and survival in cancer therapeutics. Blood. 2006 Jan;107(2):431-434. Epub 2005 Sep 8.